Investigation into the feasibility of using PRESAGE/optical-CT dosimetry for the verification of gating treatments.

Journal Article (Journal Article)

This work presents an investigation into the use of PRESAGE dosimeters with an optical-CT scanner as a 3D dosimetry system for quantitative verification of respiratory-gated treatments. The CIRS dynamic thorax phantom was modified to incorporate a moving PRESAGE dosimeter-simulating respiration motion in the lungs. A simple AP/PA lung treatment plan was delivered three times to the phantom containing a different but geometrically identical PRESAGE insert each time. Each delivery represented a treatment scenario: static, motion (free-breathing) and gated. The dose distributions, in the three dosimeters, were digitized by the optical-CT scanner. Improved optical-CT readout yielded an increased signal-to-noise ratio by a factor of 3 and decreased reconstruction artifacts compared with prior work. Independent measurements of dose distributions were obtained in the central plane using EBT film. Dose distributions were normalized to a point corresponding to the 100% isodose region prior to the measurement of dose profiles and gamma maps. These measurements were used to quantify the agreement between measured and ECLIPSE(R) dose distributions. Average gamma pass rates between PRESAGE and EBT were >99% (criteria 3% dose difference and 1.2 mm distance-to-agreement) for all three treatments. Gamma pass rates between PRESAGE and ECLIPSE(R) 3D dose distributions showed excellent agreement for the gated treatment (100% pass rate), but poor for the motion scenario (85% pass rate). This work demonstrates the feasibility of using PRESAGE/optical-CT 3D dosimetry to verify gating-enabled radiation treatments. The capability of the Varian gating system to compensate for motion in this treatment scenario was demonstrated.

Full Text

Duke Authors

Cited Authors

  • Brady, SL; Brown, WE; Clift, CG; Yoo, S; Oldham, M

Published Date

  • April 21, 2010

Published In

Volume / Issue

  • 55 / 8

Start / End Page

  • 2187 - 2201

PubMed ID

  • 20348606

Pubmed Central ID

  • PMC3018756

Electronic International Standard Serial Number (EISSN)

  • 1361-6560

Digital Object Identifier (DOI)

  • 10.1088/0031-9155/55/8/005


  • eng

Conference Location

  • England